CRVS
Corvus Pharmaceuticals, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones +1.5% · nuevas posiciones netas 0.0% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 34.72M | $518.70M | +11 | −5 |
| Q1 2026 | 64 | +8 | 30.80M | $450.00M | +15 | −7 |
| Q4 2025 | 56 | +2 | 25.04M | $192.77M | +2 | n/a |
| Q3 2025 | 14 | 0 | 18.71M | $137.91M | +2 | −2 |
| Q2 2025 | 11 | -1 | 17.31M | $69.23M | +1 | −2 |
| Q1 2025 | 9 | +2 | 6.14M | $19.53M | +2 | n/a |
| Q4 2024 | 7 | -1 | 4.46M | $23.85M | n/a | −1 |
| Q3 2024 | 7 | 0 | 7.32M | $38.63M | n/a | n/a |
| Q2 2024 | 7 | n/a | 7.37M | $13.41M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 6.45M | -8.3% | $47.57M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 2 | BlackRock ✦ (pasivo) | 4.71M | +11.1% | $34.72M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (pasivo) | 3.47M | +5.8% | $25.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (pasivo) | 1.46M | +7.0% | $10.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (pasivo) | 1.01M | +51.4% | $7.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 617.22K | n/a | $4.55M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | Goldman Sachs Group ✦ | 445.67K | n/a | $3.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 203.36K | -9.2% | $1.50M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Wellington Management ✦ | 180.18K | +76.0% | $1.33M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 10 | JPMorgan Chase ✦ | 64.46K | n/a | $475,100 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Citadel Advisors ✦ | 42.77K | Nuevo | $315,185 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 32.41K | +23.2% | $239,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 25.57K | Nuevo | $188,488 | 0.0% | New | 1 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 1.47K | +529.1% | $10,851 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Citadel Advisors | $315,185 | 0.0% |
| D. E. Shaw & Co. | $188,488 | 0.0% |
Posición cerrada
| Marshall Wace | $806,604 | era 0.0% |
| Renaissance Technologies | $660,752 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 163 tenedores, 69.83M acciones, $976.09M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.